読み込み中
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
前日終値
$24.74
+$0.79 · +3.30%
日中の時刻はETです。市場データは遅延する場合があります。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日中レンジ
現在 $24.74
52週レンジ
現在 $24.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
52
適正価値
センチメント
34
弱気
リスク
43
やや高いリスク
モメンタム
46
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
日中レンジ
現在 $24.74
52週レンジ
現在 $24.74
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.84億 USD | 3655.5万 USD | 878万 USD | 1240.5万 USD | — |
| 粗利益 | 1.84億 USD | 3655.5万 USD | 878万 USD | 1240.5万 USD | — |
| 研究開発 | 1.38億 USD | 8913.3万 USD | 8223.1万 USD | 7783.7万 USD | 5416.8万 USD |
| 販売・一般管理 | 6708.8万 USD | 4879.4万 USD | 4132.2万 USD | 3892.4万 USD | 3189.7万 USD |
| 営業費用 | 2.05億 USD | 1.38億 USD | 1.24億 USD | 1.17億 USD | 8606.5万 USD |
| 受取利息 | 1376.5万 USD | 1263.8万 USD | 990.8万 USD | 312.2万 USD | 12万 USD |
| 支払利息 | 9000 USD | — | — | — | — |
| 減価償却費と償却費 | 177万 USD | 217.7万 USD | 246.9万 USD | 154.6万 USD | 97.4万 USD |
| 営業利益 | −2059万 USD | −1.01億 USD | −1.15億 USD | −1.04億 USD | −8606.5万 USD |
| 純利益 | −688.5万 USD | −8898.1万 USD | −1.05億 USD | −1.01億 USD | −8580.5万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$51.00
上昇余地（106.14%）価格履歴は利用できません
最高：$58.00平均：$51.00最低：$44.00この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5901.32万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3473.83万0.04%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI3183.74万0.32%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF2029.21万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1219.04万0.09%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB993.13万0.09%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO987.82万0.05%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS839.74万0.02%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
